Jeremy Skillington (CEO) Poolbeg Pharma PLC (AIM:POLB) (Poolbeg Pharma PLC (AIM:POLB)) Presenting at the proactive One2One Virtual Forum - 20th January 2022
Poolbeg Pharma PLC is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables it to develop multiple products faster and more cost effectively than the traditional biotech model. The company has aspirations to become a “one-stop-shop” for Big Pharma seeking mid-stage products to license or acquire. Spun-out of Open Orphan PLC (AIM:ORPH, OTC:OPORF) and headquartered in London, Poolbeg's management team has proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation. With access to knowledge, experience and clinical data from over 20 years of Influenza, RSV, HRV and SARS-CoV-2 human challenge trials, Poolbeg uses its insights to reposition clinical stage products, reducing spend and risk.